ABSTRACT
This study was planned with
the objectives of evaluating the pattern of antimicrobials used for UTI and to
determine the recurrence rate of UTI in diabetic and nondiabetic women in our settings. New diagnosis of UTI is defined as a
patient with no prescription for UTI in the history (for 1 year) and a first prescription for UTI in the study period. A recurrent UTI was defined as a prescription for UTI in the follow-up period (5 days after the first prescription until
30 days after the end of the first prescription) or hospitalization admission with the diagnosis of a UTI. Among 220
patients, 106(48.18%) had recurrence.
Out of these patients, 74 were diabetics (74%) and the remaining were
nondiabetics (26.67%).
Recurrent UTI was more frequent in diabetics of above 50 years group. Duration antimicrobial therapy was significantly longer in diabetics. Most commonly used antibiotic group is cephalosporins
in both diabetics as well as
non-diabetics.
INTRODUCTION
Urinary tract infection (UTI) is the most common bacterial infection encountered
in clinical practice.[1]
Approximately half of all women have at least one
symptomatic UTI during their lifetime.[2] Relapse or
reinfections are also a major concern. Many women experience relapses or reinfections of the lower urinary tract even after treatment with broad-spectrum antibiotics.[3] Diabetes has been associated
with an increased risk of UTI due to various predisposing factors, such as hyperglycemia related
impairment of the immune response and glucosuria.[4,5] A Dutch study showed that despite the
fact that patients with diabetes more often received
longer and more potent initial treatment than patients without diabetes, women with diabetes more often
had recurrences of UTIs.[6] Despite guidelines/recommendations for the optimal selection of an antimicrobial agent and duration of therapy for
UTI, studies demonstrate a wide variation
in prescribing practice.[7,8] In clinical practice,
empirical therapy is prescribed either
without a urine culture
and susceptibility testing or before such result is known. Clinical trials demonstrating the optimal antibiotic therapy for UTIs in diabetic patients are
scanty. Current antibiotic recommendations for UTIs based
on the expertâs opinion. Since the resistance
patterns of microbial causing uncomplicated UTI
vary considerably between regions and countries, a specific treatment recommendation may not be universally suitable for all regions or countries.[6,9] With the increase in the incidence of type 2 diabetes mellitus, there is a chance for increased risk of UTI
among these patients adding economical burden.[10]
High rates of irrational antibiotic prescription for UTI in these patients
may lead to the development of
bacterial resistance to most valuable antibiotics. Since the pattern of bacterial resistance varies in different regions, there is a need to gather data on
pattern of antibiotic use and response to therapy in
UTIs in different regional settings. This study was planned with the objectives of evaluating the pattern
of antimicrobials used for UTI and to determine the recurrence rate of UTI in diabetic and nondiabetic
women in
our settings.
MATERIALS AND METHODS
This retrospective medical
record based study was
conducted at a tertiary care teaching hospital in South India.
The study was conducted after getting approval
from the Institutional ethics committee. All women
aged â¥18 years with and without diabetes with at-least
one episode of UTI were included in
the
study.
The following patients were excluded from the study: · Pregnancy
· Patients with known anatomical
abnormalities,
indwelling urinary catheter
· Patients on antiretroviral therapy, immune suppressive drugs, chemotherapy during UTI and in the
last 1 year
· Patients receiving a first prescription with duration
of >30 days.
· Patients with a second prescription within 5 days after
their first prescription
· Women with complicated UTI [defined as
pyelonephritis or as infections with an
invasive systemic
presentation)[19]
Data was collected
from the medical record department for the period of 2010 January to
December 2014. All diagnoses were coded according
ICD-10 which enabled us to identify
patients with
UTIs. The entry date into the study was the day that
the
patient received her first prescription for UTI. The history period was 1 year before study inclusion. Patients with diabetes were defined by prescription of one or more antidiabetic agents in the
history.
New diagnosis of UTI is defined as a patient with no prescription for UTI in the history (for 1 year) and a
first prescription for UTI in the study period. A
recurrent UTI was defined as a prescription for UTI in the follow-up period (5 days after the first
prescription until 30 days after the end of the first
prescription) or hospitalization admission with the diagnosis of a UTI. These recurrences could be
relapses (second infection with the
same
organism) or
reinfections (second infection with a different organism). Hence, recurrent UTI is considered if
there is prescription for UTI within 6 to 30 days of
the 1st episode.
Statistical Analysis: The clinical characteristics of
the
study population were calculated
as proportions or means (±SD).
The pattern of antibiotic
prescription was presented as a categorical variable for first or
recurrent episodes of UTI. Antibiotic use and the
recurrence rate were compared between women with
and without diabetes. Analyses were done with a chi square
test for categorical variables and student âtâ test for continuous variables. Subgroup analyses were
done
by categorizing the patients into different age strata. A P-value <0.05 was considered to indicate statistical significance.
RESULTS
A total of 220 patients was included in the study.
Among them, 120 were nondiabetics and 100 were
diabetics. The mean age of diabetics was 58.51±12.11 years,
whereas
in
nondiabetics
39.19±14.44 years. In diabetics, majority of the patients were above 60 years, whereas in diabetics
majority were between 31-40 year(table 1). Table 2
shows the distribution of patients
with recurrent
UTIs. Among 220 patients, 106(48.18%) had recurrence. Out of these patients, 74 were diabetics (74%) and the
remaining were nondiabetics (26.67%). Recurrent UTI was more frequent in
diabetics of above 50 years group. In nondiabetics
also, recurrence was more in patients
above the age
of 60 years.
The urine culture reports were negative in 78% of diabetic patients and 95% of nondiabetics. The
positive urine cultures showed E.coli in most cases (table 3). Most commonly used antibiotic group is cephalosporins in both diabetics as well as non-diabetic. There was statistically significant difference
between the two groups in the use of cephalosporins,
fluroquinolones, carbapenems and nitrafurantoin. The use of cephalosporins and carbapenems was more in diabetics compared to nondiabetics. Similarly,
fluroquinolones and nitrofurantoin
was more often used
in nondiabetics than diabetics.
Among the diabetics, 20 patients received a combination of two antibiotics, whereas 26 (21.7%)
of nondiabetic patients received a combination of two
antibiotics. Fluroquinolones were used in the combination only in nondiabetic patients,
whereas carbapenems, clindamycin and azithromycin were used as a combination,
only in
diabetic patients.
Table 5 shows the type of cephalosporins used. Cefaperazone in combination with sulbactum was the
most commonly used cephalosporin followed by cefotaxime in both the
groups.
Table 6 shows the type of penicillins and fluroquinolones used. Ciprofloxacin is the most commonly used fluroquinolones followed by ofloxacin and norfloxacin. Among the penicillins,
piperacillin in combination with tazobactum was most commonly used.
Duration antimicrobial therapy was 6.62±3.36 days in
non
diabetics whereas it is 8.14±3.53
days in diabetic
women, the difference
being statistically very
significant (p<0.001, student âtâ test).
The patients who had recurrent UTI have received a longer
duration of antimicrobial therapy compared to those
who
did not have recurrent
UTI (7.82±3.6 days vs
6.83± 3.37 days), the difference is statistically
significant (p=0.037). When duration of therapy was
compared between two groups after categorizing as
short (>5 days) and long(>5days), a higher proportion of diabetic women received long duration
of therapy when compared to their nondiabetic counterparts (80% vs 61.7%), the difference being statistically
significant (p=0.003, X2 test).
Table 7 shows the comparison of glycaemic
parameters in diabetic with and without recurrent UTI. Though the HbA1c and postprandial
blood sugar were higher in patients with recurrent UTI, the
differences were statistically not significant. The fasting blood sugar was higher in patients without recurrent UTI, but again the difference was
statistically not significant.
DISCUSSION
Urinary tract infection is one of the common
infections seen in women, especially in the presence of diabetes mellitus.
Most often uncomplicated
UTI is treated empirically without the evidence of
susceptibility of causative agent to antibiotics used. The present study was aimed at comparing the pattern of antibiotic use and the recurrence
rate among women with and without
diabetes mellitus.
The present study showed that the prevalence of UTI is more in the age group of 20-40yeras in nondiabetics whereas in diabetics, the majority of
patients with UTI were above 50 years. This observed difference,
obviously due to the fact that the
UTI
is more common in sexually active age group
and the number of diabetic patients in this age group is much less compared to nondiabetic group. In the
age group of above 40 years, there were more diabetics than nondiabetics, suggesting a higher prevalence of UTI in diabetic women.
Epidemiological studies have shown that UTI is more
common in diabetic females than their nondiabetic
counterpart.[11] High glucose levels in the renal
parenchyma favours the growth and multiplication of microorganisms. Impairment in the immune system
also contributes to the growth of microorganism. Autonomic neuropathy leading to dysfunctional
bladder voiding
and retention of urine enhances the risk
of UTI due decreased physical clearance of microorganism
through micturition.[12]
Geerlings SE, et al suggested to consider
UTI as a complication in women with diabetes based on the higher prevalence asymptomatic bacteriruria in
diabetic women observed
in their studies.[13] Similar observations were seen in another study conducted in Iranian population. The authors of this study recommended routine urine culture for diabetic
women even when there is no urinary symptom.[14]
The diagnosis of UTI is primarily based on signs and symptoms rather than isolated laboratory findings. Urine
cultures may not be useful for acute uncomplicated cystitis, but recommended for patients
with uncomplicated pyelonephritis and complicated
UTI. [15] In accordance
with this fact, our findings
also shown that in the majority of the patients of both groups, the urine culture was negative and the diagnosis of UTI is based on clinical symptoms and
the
routine urine analysis. Hence, most of the patients received empirical
antimicrobial treatment.
The most commonly used antimicrobials were cephalosporins in both diabetics and nondiabetics.
Fluroquinolones are less commonly used in diabetics
when compared to their nondiabetic counterparts. As
a general rule, treatment of UTI in diabetic patients is
similar to that of UTI in non-diabetic patients. The
antibiotic choice should be guided
by local susceptibility patterns of uropathogens.
Nitrofurantoin, cotrimoxazole, fosphomycin are used as
first line agents for acute cystitis;cirpfloxacin, ofloxacin,gentamicin, cefuroxime
are used for uncomplicated pyelonephritis;ciprofloxacin, oofloxacin, gentamicin,amikacin, piperacillin-tazobactum, ertapenem used
for complicated
pyelonephritis.[16]
The present study showed that the selection of
antimicrobials was largely according to the guidelines. However, cefoperazone was the most
commonly used cephalosporin against the
recommended cephalosporin i.e, cefuroxime. Around 20% of our patients in both the groups,
received a combination of two antibiotics. The most appropriate antibiotic should be selected for the empirical treatment of UTI. The empiric prescribing of broad spectrum agent or use of combination of antibiotic to
broaden
the spectrum should
be avoided to reduce
the selection of resistant bacteria. Moreover, critically
important antibiotics,such as carbapenems, aminoglycosides
should be restricted
to the most
severe infections and always be preceded by a susceptibility test. In our study, 6% of diabetics
received these antibiotics.
Due to the increasing
prevalence of antibiotic- resistant bacteria,
particularly the extended spectrum beta-lactamase
producing gram-negative bacteria, it is crucial to
avoid antibiotic overprescribing.
The majority of our patients were on parenteral
antibiotics. Pyelonephritis in diabetic patients may be
treated with oral antibiotics in patients with mildâ moderate symptoms, with no alterations in gastrointestinal absorption. However, diabetic patients with
severe symptoms, hemodynamic
instability,
metabolic
disturbances should
be hospitalized
for initial intravenous antibiotic therapy
and those with severe sepsis or known to be having a
UTI
with resistant bacteria should receive
broad-spectrum coverage. Treatment should be modified
when
culture
results are available.[12]
Our study showed that diabetic women had received
a longer duration of antimicrobial therapy for their
UTI
when compared to nondiabetic women. The recommended duration of antibiotic treatment for UTI is similar to that of non-diabetic patients (upto 7
days for uncomplicated
UTIs and 10-14 days for complicated UTIs). For the treatment of uncomplicated cystitis, short-course regimens (single dose to 5 days) are recommended as first-line therapy and are as effective as longer antimicrobial
regimens.[12,17]
Though some argue that patients
with diabetes
mellitus should receive longer antibiotic treatment
than patients without diabetes mellitus, randomized
controlled trials are lacking.[18]
Despite
receiving longer duration of treatment as well as critically important antibiotics, the recurrence
rate of UTI was higher in diabetics than nondiabetics. Schneeberger C, et al also reported higher recurrence
rate of UTIs in diabetic women. [6] However, Raz R, et al did not find diabetes as
a risk
factor for recurrent UTI in postmenopausal diabetic women.[19] Our findings did not suggest a correlation between recurrence
rate of UTI and glycaemic
control. Several studies did not find an association between glycaemic control
and UTI in diabetics.[20,21]
CONCLUSIONS
The UTI in diabetics is more common above the age
of 50 years. Parenteral cephalosporins were the most commonly used antibiotic irrespective of diabetic status. The diabetic patients received a longer duration of treatment than nondiabetics. The recurrence rate of UTI is more in diabetics. There was no correlation between glycaemic control and
recurrence rate
of UTI in diabetic females.
Table 1 Agewise
distribution of patients
X2 test *p<0.0001
Table 2: Distribution of patients
with
recurrent urinary tract infections
X2 test *p<0.0001
Table 3: Urine culture reports
Patient groups |
No growth n (%) |
Growth of E.coli n (%) |
Growth of Klebsiellae n (%) |
Diabetics (n=100) |
78 (78) |
21 (21)* |
1 (1) |
Non-diabetics (n=120) |
114 (95) |
5 (4.2) |
1 (0.8) |
Total |
192 (87.27) |
26 (11.81) |
2 (0.91) |
Table 4: Pattern of antimicrobial used
Antimicrobial class |
Diabetics n(%) |
Non-diabetics n(%) |
Total n(%) |
Fluroquinolones |
7 (7) |
38 (31.7)** |
45(20.5) |
Cephalosporins |
67(67) |
41(34.2)* |
108(49.1) |
Penicillins |
9 (9) |
9(7.5) |
18 (8.2) |
Tetracyclines (doxycycline) |
1 (1) |
4(3.3) |
5(2.3) |
Carbapenems |
5 (5) |
0* |
5 (2.3) |
Cotrimoxazole |
8 (8) |
11 (9.2) |
19 (8.6) |
Aminoglycosides (amikacin) |
1 (1) |
0 |
1 (0.5) |
Nitrofurantoin |
1 (1) |
11 (9.2)* |
12 (5.5) |
Macrolides (Azithromycin) |
1 (1) |
2 (1.7) |
3 (1.4) |
Clindamycin |
0 |
4 (3.3) |
4 (1.8) |
Table 5: Type of cephalosporins used
Type of cephalosporins |
Diabetics n(%) |
Non-diabetics n(%) |
Total n(%) |
Cefaperazone+sulbactum |
34 (34) |
14 (11.7) |
48(21.82) |
Cefotaxime |
13 (13) |
10 (8.3) |
23(10.46) |
Ceftazidine+tazobactum |
3(3) |
1 (0.8) |
4(1.82) |
Cefuroxime |
2 (2) |
3(2.5) |
5(2.27) |
Cefixime+clavulanic acid |
4 (4) |
4(3.3) |
8(3.64) |
Ceftriaxone+tazobactum |
11 (11) |
7 (5.8) |
18 (8.18) |
Cefpodoxime+clavulanic acid |
1 (1) |
1 (0.8) |
2 (0.91) |
Table 6:Type of penicillins and fluroquinolones used
Type of penicillins/ fluroquinolones |
Diabetics n(%) |
Non-diabetics n(%) |
Total n (%) |
Amoxicillin |
2 (2) |
1 (0.8) |
3 (1.36) |
Piperacillin+tazobactum |
5 (5) |
6 (5) |
11 (5) |
Ampicillin |
0 |
1 (0.8) |
1 (0.46) |
Cloxacillin |
1 (1) |
0 |
1 (0.46) |
Norfloxacin |
2 (2) |
9 (7.5) |
11 (5) |
Ofloxacin |
0 |
11 (9.2) |
11 (5) |
Ciprofloxacin |
4 (4) |
18 (15) |
22 (10) |
Sparfloxacin |
1 (1) |
0 |
1 (0.46) |
Table 7: Comparison of glycaemic parameters in diabetic with and without recurrent UTI
Glycaemic parameters |
Patients with recurrent UTI |
Patients without recurrent UTI |
HbA1c (%) |
9.84±2.20 |
9.47±1.69 |
Fasting blood sugar (mg/dl) |
170.63±79.93 |
205.26±68.61 |
Post prandial blood sugar (mg/dl) |
266.42±109.92 |
258.50±85.58 |